ImmuneOncia Faces Disclosure Violator Designation Over Two Late Clinical Trial Filings
Bitget2026/10/28 09:37- ImmuneOncia Therapeutics faces designation as a disclosure violator under an Oct. 28, 2026, notice; a decision is due Nov. 20, 2026.
- Late disclosures concerned clinical trial amendment application on July 1 and approval on Aug. 4; both disclosed Sept. 14, 2026.
- Final designation with at least eight penalty points could trigger a one-day trading halt.
- Annual penalty points total zero; reaching 10, including this case, could trigger a listing eligibility review.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Pyth October Report: ARR Jumps 18.9% as Data Expansion Accelerates
Elon Musk: SpaceX (SPCX.US) Q4 revenue is expected to increase by approximately 70% quarter-on-quarter, with government contract income share falling below 10%
Elon Musk stated on Friday that SpaceX (SPCX.US) will continue to reduce its dependence on U.S. government procurement contracts.
After the sharp decline in tech stocks, the White House suddenly canceled the top tech advisor meeting the following day.
The White House has canceled the previously scheduled President’s Council of Advisors on Science and Technology meeting, which was set for Friday and includes prominent tech leaders such as Nvidia CEO Jensen Huang and Meta CEO Mark Zuckerberg. The Department of Energy's meeting page briefly listed November 13 as the new meeting date, but the agency later sent an email retracting this information. Currently, the specific date for rescheduling the meeting remains unclear.
Crypto prices
More
